Providence, Humana Launch Initiative to Standardize Payer-Provider Data Sharing

Providence and Humana launched a new initiative to standardize and streamline data exchange between payers and providers. The program leverages FHIR-based APIs to create a scalable, real-time system that can be replicated across other healthcare organizations nationwide. The post Providence, Humana Launch Initiative to Standardize Payer-Provider Data Sharing appeared first on MedCity News.

Read More

Concierge Care for all: What would it look like?

By MATTHEW HOLT A few weeks back I wrote an article on what’s wrong with primary care and how we should fix it. The tl:dr version was to give every American a concierge primary care physician paid for by the government. We would give everyone a $2k voucher (on average, dependent on age, medical status,…

Read More

Private Medicare, Medicaid Plans Exaggerate In-Network Mental Health Options, Watchdogs Say

Companies running private Medicare and Medicaid insurance plans inaccurately list many mental health professionals as being available to treat the plans’ members, a new federal watchdog report says. The investigators allege that some insurers effectively set up “ghost networks” of psychologists, psychiatrists, and other mental health professionals who purportedly have agreed to treat patients covered…

Read More

Ex-Cano Health CEO on Trial Amid $72M Fraud Claims

Marlow Hernandez, the founder and former CEO of Cano Health, is facing a jury trial this week over allegations that he fraudulently enriched himself and his family while managing the senior-focused primary care company. Cano filed for bankruptcy last year — an event many industry experts attributed to Hernandez’ poor governance. The post Ex-Cano Health…

Read More

BioCryst’s $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE

BioCryst Pharmaceuticals’ Astria Therapeutics acquisition brings navenibart, a drug in Phase 3 testing for the rare disease hereditary angioedema. The injectable antibody has the potential to match the efficacy of the blockbuster Takeda Pharmaceutical drug that currently dominates the market, but with less burdensome dosing that could encourage HAE patients to switch. The post BioCryst’s…

Read More